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Introduction
Hereditary sensorimotor neuropathies are collectively known as Charcot-Marie-Tooth disease (CMT). Based on nerve conduction velocities, the disease can be divided into demyelinating CMT (CMT1), axonal CMT (CMT2) and intermediate CMT (Reilly et al., 2011) . All forms of Mendelian inheritance are possible. Autosomal recessive CMT is typically more severe than the autosomal dominant forms, often with onset in early childhood and severe symptoms such as skeletal deformities and loss of ambulation before adulthood (Tazir et al., 2013) . Although more than 70 disease genes for CMT are known, a large number of affected individuals remain without a genetic diagnosis, particularly in CMT2, suggesting that undiscovered disease genes remain (Rossor et al., 2013) .
Germinal center associated nuclear protein (GANP) is a multi-domain 208 kDa protein that localizes predominantly to the nucleus and is encoded by 28 exons of MCM3AP at chromosome 21q22.3 (Abe et al., 2000) . MCM3AP is ubiquitously expressed (Abe et al., 2000) , but the exact functions of GANP in various tissues remain incompletely understood. GANP has been described to serve as a scaffold for transcription export 2 (TREX-2) complex involved in the export of mRNAs from the nucleus to the cytoplasm (Wickramasinghe et al., 2010; Umlauf et al., 2013) . In addition, GANP may associate with NXF1 (nuclear RNA export factor 1) to facilitate the transport of mRNAs from the nuclear interior to the nuclear pores (Wickramasinghe et al., 2010; Jani et al., 2012) . In B cells, GANP has been shown to favour transcription complex recruitment and chromatin remodelling at rearranged immunoglobulin variable loci (Singh et al., 2013 ).
An exome sequencing study by Schuurs-Hoeijmakers et al. (2013) investigated families with intellectually disabled siblings, and among their potentially pathogenic findings reported a homozygous MCM3AP missense change p.Glu915Lys in an affected sibling pair with progressive polyneuropathy. Another recent study proposed that a de novo p.Pro443Ser variant in MCM3AP in combination with a de novo variant in POMP, encoding a proteasome maturation protein, led to a DNA repair deficit in a child who suffered from immune deficiency (Gatz et al., 2016) . The pathogenic role of the MCM3AP variants in the former studies is unclear, and thus this gene has not yet been conclusively implicated in human disease.
We present here evidence in multiple families, establishing MCM3AP as a disease gene for autosomal recessive CMT and intellectual disability.
Materials and methods

Patients and sequencing
We studied patients from five families of Finnish (Family F), Australian (Family A), Canadian (Family C), Dutch (Family N) and Turkish (Family T) origin (Fig. 1A) . Our study was conducted in accordance with the Declaration of Helsinki, and all participating individuals or their guardians gave written informed consent to participate. The study was approved by the institutional ethics boards. The collaboration was partly established through investigators sharing their genes of interest through the GeneMatcher (Sobreira et al., 2015) .
Whole exome sequencing (WES) was performed for Patients F:II-3, F:II-4, F:II-5, A:II-2, N:II-1, C:II-1, T:II-1, and T:II-2, for each family independently. Details of the sequencing methods are in the Supplementary material. MCM3AP variants were confirmed by Sanger sequencing; primer sequences are supplied in the Supplementary material.
Skin fibroblast culture and analysis of RNA and protein Fibroblast cultures were established from skin punch biopsies by standard methods. Following RNA isolation and cDNA synthesis, cDNA was sequenced with primers specific for exons 1-2 and 16-18 for Family F fibroblasts, and exons 9-10 for Family A fibroblasts. Quantitative PCR (qPCR) was done using DyNAmo TM Flash (Thermo Scientific). Detailed methods and primer sequences are in the Supplementary material. Western blotting was performed with sheep anti-GANP primary antibody provided by Dr Vihandha Wickramasinghe, University of Cambridge. To inhibit nonsense-mediated decay (NMD), cells were treated with cycloheximide (CHX) 20 mg/ ml (Sigma) for 24 h. Proteasome inhibition with MG132 was performed as previously described (Ylikallio et al., 2013) .
Minigene mRNA splicing assay MCM3AP exon 5 and flanking intronic sequences were inserted into pSPL3 minigene vector (Hansen et al., 2008; Wang et al., 2015) , a kind gift from Dr Thomas v. O. Hansen. Mutagenesis was used to introduce the splice donor variant c.1857A4G, p.Q619= into exon 5. Two micrograms of plasmids containing the mutated or wild-type exon 5 were transfected into 143B cells with jetPRIME Õ kit (Polyplus).
RNA was isolated 24 h later with NucleoSpin Õ kit (Macherey-Nagel) and RT-PCR performed to detect the effects on splicing. Details of the experiment and vector map are supplied in the Supplementary material.
Mixed neuronal cultures from human induced pluripotent stem cells
To establish a neuronal culture, a previously characterized human induced pluripotent stem cell (iPSC) line HEL11.4 (Mikkola et al., 2013) was differentiated towards neuronal lineage according to Hamalainen et al. (2013) . Full methods are included in the Supplementary material. Neuronal cells were identified using immunocytochemistry with antibody against neuron-specific class III b-tubulin (TUJ1, #801201, BioSite), and GANP was detected using an N-terminal antibody (#ab198173, Abcam).
DNA damage repair
To study DNA damage repair, we used fibroblasts from Patients F:II-3 and F:II-4. Three unrelated normal fibroblast lines served as negative controls, and fibroblasts derived from a xeroderma pigmentosum group C (XPC) patient (Coriell Institute Cell repository, GM16684) and from a DNA ligase 4 syndrome (LIG4) patient (Coriell Institute Cell repository, GM16088) as positive controls for sensitivity to UV and ionizing radiation, respectively. Experimental details are provided in the Supplementary material.
Results
Clinical findings
The affected individuals (Fig. 1A) presented with multiple neurological and variable degrees of non-neurological signs and symptoms. The clinical features are summarized in Table 1 . Results from nerve conduction studies are given in Table 2 , and detailed case descriptions in the Supplementary material. Sensorimotor neuropathy was a prominent feature in all affected individuals. Nerve conduction studies showed axonal neuropathy in Families F, A, N and C. In Family T, nerve conduction studies of Subject T:II-1 was done at an advanced stage of the disease and thus nerve conduction velocities were unobtainable. In Patient T:II-2, median motor nerve conduction velocity was decreased to 23 m/s, consistent with a demyelinating component. Patient N:II-1 also had decreased median nerve conduction velocities suggesting demyelination in addition to the axonal degeneration. The affected individuals had severe and progressive distal muscle weakness and atrophy in hands and feet. Motor development was delayed, and independent ambulation was generally lost between ages 10-24 years. Besides CMT, the second most consistent finding was intellectual disability, which was found in seven of nine affected individuals (Supplementary Table  1 ). The intellectual disability was generally mild to moderate, although more severe intellectual disability was seen in two older patients in Family C. In addition, two individuals (Patients F:II-3 and A:II-2) manifested with delayed speech development and learning difficulties.
Genetic findings
Sequencing revealed MCM3AP variants segregating with the phenotype in all families. The variants in Family F were a single nucleotide deletion c.443delC p.Pro148Leufs*48 predicting a frameshift and premature stop in the FG-repeat domain of GANP ( (Fig. 1A ).
In the affected Patient A:II-2, we found a nonsense variant c.2667C4A p.Tyr889* and a missense variant c.2600C4A p.Ala867Asp. Neither variant was present in ExAC. The p.Ala867Asp variant was maternally inherited, and the frameshift variant was found to be de novo. This was confirmed using a second independent sample of the patient and father, and family relationships were confirmed using single nucleotide polymorphism (SNP) duo analysis. The missense change p.Ala867Asp, which locates in the Sac3 (suppressor of actin 3) domain of GANP (Fig. 1B) , received a CADD C-score of 28.1.
The affected individual from Family N was compound heterozygous for the c.1857A4G p.Gln619= variant, and a single nucleotide insertion c.3949_3950insG p.Asn1317fs*18, both of which were absent in ExAC. The latter change, located in exon 18, predicted a frameshift and a premature stop codon. The c.1857A4G variant was positioned in the splice donor position of exon 5. In silico prediction with the Human Splicing Finder version 3.0 suggested that the variant creates an exonic splicing silencer site, suggesting a splicing defect with a likely consequence on mRNA stability. In Family C, the siblings were compound heterozygous for a nonsense variant c.4433C4A p.Ser1478* in exon 21, and a missense variant c.4729G4A p.Glu1577Lys. The stop variant was not included in ExAC, whereas the missense variant was present twice (frequency 1.653 Â 10 À5 ) with a CADD score of 24.4. Sanger sequencing confirmed the variants in the affected siblings, and their unaffected mother was a carrier of the nonsense variant.
Finally, in Family T two siblings were homozygous for the missense variant c.2285T4C p.Met762Thr in exon 8. This variant was not present in ExAC, but a variant in the same codon, p.Met762Leu, had a carrier frequency of 1.651 Â 10
À5
. The p.Met762Thr variant received a CADD C-score of 25.4.
All MCM3AP variants and the evidence of their pathogenicity are summarized in Supplementary Table 2. MCM3AP variants lead to severe depletion of GANP protein Skin fibroblasts from affected Patients F:II-3, F:II-4 and A:II-2 in Families F and A were available for testing the effects of the compound heterozygosity on mRNA and protein level. The presence of nonsense variants in these two families suggested the possibility of NMD. Unexpectedly in Family F, the sequencing of MCM3AP cDNA showed that mRNAs containing variants c.443delC or c.3814G4A were present in the fibroblasts of the affected individuals ( Fig. 2A) . Therefore, the nonsense variant c.443delC at least partially escaped NMD, possibly due to its location in exon 1. Variants in the first exon of a gene may escape NMD as the result of inability to recruit essential NMD factors to exon 1 termination sites, enabling translation to start from an alternative downstream start site (Kozak, 1987; Neu-Yilik et al., 2011) . Western blots showed no smaller bands below the full length GANP, suggesting that the frameshift mRNA in Family F did not produce a stable truncated protein (Fig. 2C) . However, we found the total MCM3AP mRNA levels to be reduced to $50% and GANP protein levels to $20% of the control levels ( Fig. 2B-D) . As both alleles could still be detected by cDNA sequencing, it is likely that both mutations partially contributed to the mRNA and protein instability. The level of GANP was not restored by inhibiting the proteasome with MG132, suggesting a mechanism other than proteasomal degradation (Fig. 2D) . Hence in Family F, the compound heterozygosity of the mutations results in a severe reduction in the amount of GANP protein.
Sequencing of fibroblast cDNA from Patient A:II-2 showed homozygosity for the c.2600C4A p.(Ala867Asp) variant. Accordingly, the total MCM3AP mRNA level was $50% of control level (Fig. 2B) . Treatment of Patient A:II-2 fibroblasts with the NMD inhibitor CHX restored the stability of the nonsense mutant mRNA (Fig. 2A) . This showed that the c.2667C4A p.Tyr889* mRNA was degraded through NMD, as expected when the stop codon is in the middle of the gene. The level of GANP was also decreased in patient's cells but only to $85% of the control levels ( Fig. 2C and D) , potentially as a result of compensatory increase in the stability of the protein produced by the missense allele.
Skin fibroblasts from other affected individuals were not available for investigation of the effects of the identified variants. It is, however, noteworthy that also in Family C, one of the compound heterozygous variants is predicted to directly affect the GANP protein level through mRNA instability, and in Family N, a frameshift variant was found in combination with a probable splicing variant. Using a minigene splicing assay, we confirmed that the donor splice site mutation in exon 5 causes the skipping of that exon (Fig. 2E) , resulting in a frameshift and a premature stop codon p.Ser557fs21*. The minigene assay suggested that the mutant transcript is in part spliced normally, therefore some functional protein is likely to be produced. The missense variants found in Families A, C and T affected conserved residues (Fig. 1C) and received high pathogenicity prediction scores. The variants p.Ala867Asp (Family A) and p.Met762Thr (Family T) localize to the Sac3 domain (Fig. 1B) , needed for interaction with TREX-2 components, while p.Glu1577Lys (Family C) is in the C-terminal region of GANP, which is needed for localization to the nuclear envelope (Jani et al., 2012) . The missense variants are therefore expected to be deleterious for protein function, but their functional effects need to be addressed in future studies. Particularly, the association of the homozygous p.Met762Thr variant with demyelinating CMT requires confirmation in additional families. In conclusion, our results suggest that the mechanisms of disease variants in our affected individuals are related to partial depletion of the GANP protein and/or its loss of function.
GANP localizes to the nuclear envelope in cultured human neurons
The function of GANP has not been previously investigated in the human nervous system. It is reported as a ubiquitously expressed protein (Abe et al., 2000) and we confirmed by immunocytochemistry in human iPSCs differentiated towards a neuronal lineage that it is also expressed in human neurons. Neurons detected by co-staining with neuron-specific marker TUJ1 showed punctate immunoreactivity of GANP at the nuclear envelope (Fig. 2F ), consistent with its described role in nuclear pore complexes.
Severe depletion of GANP does not compromise DNA repair MCM3AP has previously been linked to a DNA repair defect (Gatz et al., 2016) , and thus we asked if the significant depletion of GANP observed in the cells from affected individuals in Family F led to sensitivity to DNA damage. When subjected to UV or ionizing radiation treatment, the cells from Patients F:II-3 and F:II-4 behaved similar to healthy control cells, and no defect in the repair of DNA damage could be identified (Supplementary Fig. 1 ). This result indicates that severe depletion of GANP does not impair the ability to repair these types of DNA damage.
Discussion
Our results demonstrate that MCM3AP mutations cause early-onset recessive CMT with intellectual disability. Variable additional clinical features included pyramidal signs and brain MRI abnormalities. Affected individuals in Family C had primary ovarian failure and Patient F:II-4 had increased gonadotropin levels; however, gonadotropin levels were not measured in the other affected individuals and thus we cannot conclude that gonadal failure is a consequence of the MCM3AP variants. The sensorimotor neuropathy was predominantly axonal except in Family T, where decreased nerve conduction velocities suggested demyelination. Indications of demyelination were also detected in Patients C:II-2 and N:II-1. Thus, recessive loss-of-function variants in MCM3AP should be considered as a cause in patients with either axonal or demyelinating features and autosomal recessive inheritance (CMT4). Variants in GDAP1 can also cause demyelinating CMT4A (Baxter et al., 2002) , axonal CMT2K (Cuesta et al., 2002; Claramunt et al., 2005) , or intermediate CMT type A (Nelis et al., 2002) . The causality of either axonal, demyelinating or intermediate phenotypes is also well documented for variants in MPZ (Shy et al., 2004) . Similarly, NEFL variants cause predominantly axonal neuropathy but nerve conduction velocities can sometimes be decreased to the CMT1 range (Mersiyanova et al., 2000; Jordanova et al., 2003) . GJB1 is another gene associated with both axonal and demyelinating forms (Ionasescu et al., 1994) . The identification of both axonal and demyelinating phenotypes for the same disease gene suggests a defect in the interplay between axons and glia. It is also possible that the observed decrease of nerve conduction velocities in the patients reported here is caused by loss of myelin that develops secondary to severe degeneration of axons.
Neuropathy has been described as a common comorbidity in intellectual disability (Chiurazzi and Pirozzi, 2016) . However, it is uncommon for affected individuals diagnosed with CMT to have concomitant intellectual disability. For MFN2 variants, which are the most common cause of CMT2 (CMT2A2) (Zuchner et al., 2006; Rossor et al., 2013) , cases of intellectual disability and cerebral MRI abnormalities together with CMT have been reported (Brockmann et al., 2008; Del Bo et al., 2008; Tufano et al., 2015) . Variants in DYNC1H1 are known to cause a spectrum of diseases that includes spinal muscular atrophy with lower extremity predominance (SMA-LED) (Harms et al., 2012) , intellectual disability with malformations of cortical development (MCD) (Poirier et al., 2013) , and CMT2O (Weedon et al., 2011) . Speech delay and/or learning difficulties were reported in some individuals with SMA-LED or CMT2O (Weedon et al., 2011; Harms et al., 2012) , and several individuals with MCD also had neuropathy (Poirier et al., 2013) . Furthermore, Cowchock syndrome (CMTX4) consists of CMT in combination with intellectual disability and sensorineural hearing loss (Cowchock et al., 1985) . Lastly, giant axonal neuropathy is a disorder caused by recessively inherited variants in GAN (Bomont et al., 2000) , which can present with a severe CMT2-resembling neuropathy and multiple additional symptoms and signs including curly hair, CNS manifestations and intellectual disability (Vijaykumar et al., 2015) . Our findings add MCM3AP to the disease genes associated with CMT and intellectual disability. The identification of variants in five families of various ethnicities suggests that MCM3AP may not be an uncommon disease gene for this clinical presentation. Our results suggest that GANP has an important role in the development of the nervous system in addition to its previously identified physiologic role in B cell antibody maturation (Singh et al., 2013) . GANP expression has been detected in the brain (Abe et al., 2000) , but its function in neural cells has not been characterized. We show that GANP localizes to the nuclear envelope in cultured human neurons. Involvement in DNA repair has been suggested for GANP (Eid et al., 2014; Gatz et al., 2016) as well as for another recently identified CMT gene MORC2 (Li et al., 2012; Albulym et al., 2016; Sevilla et al., 2016) , suggesting these genes may share a common pathway as the underlying cause for CMT. However, our results in this study do not support a role for a DNA repair defect in GANP deficiency. Interestingly, a study in Drosophila identified the orthologue of MCM3AP, xmas-2, to suppress the toxic effect of cytoplasmic accumulation of TDP-43 (TAR DNA binding protein 43 kDa, encoded by TBPH) in fly motor neurons, fitting with xmas-2 having a crucial role in the nuclear export of TBPH mRNA in neurons (Sreedharan et al., 2015) . GANP could thus be involved in the regulation of mRNA export also in human neurons. Defects of RNA metabolism have been previously implicated in motor neuron degeneration (Strong, 2010) . In particular, GLE1, which is mutated in foetal motor neuron disease (Nousiainen et al., 2008) or amyotrophic lateral sclerosis (ALS) (Kaneb et al., 2015) , encodes a factor that is essential for mRNA export (Folkmann et al., 2013) . Moreover, a recent study showed that disordered nucleocytoplasmic transport may contribute to the neurodegeneration caused by protein aggregates in the cytoplasm (Woerner et al., 2016) . Thus, it is conceivable that GANP dysfunction leading to nuclear retention of mRNAs that are crucial for neuronal function is the cause of axonal degeneration in our affected individuals. Further studies are needed to elucidate the identity of the particular mRNAs, or other potential roles of GANP in neurons.
In summary, we have identified recessive mutations MCM3AP associated with neuropathy and intellectual disability and a functional decrease of GANP protein.
Our findings propose a new molecular mechanism for neuropathy involving mRNA export from the nucleus.
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